Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …

China's population has rapidly aged over the recent decades of social and economic
development as neurodegenerative disorders have proliferated, especially Alzheimer's …

Blood biomarkers indicative of Alzheimer's disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …

Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …

The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer's disease (AD) pathophysiology …

Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging
systems. Using the topographical information from [18F] MK6240 tau positron-emission …

Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …

Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as …

Introduction Plasma biomarkers will likely revolutionize the diagnostic work‐up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …

Staging the severity of Alzheimer's disease pathology using biomarkers is useful for
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …